Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free | Novus Biologicals NB100-56505 product information

product summary

company name :

Novus Biologicals

other brands :

IMGENEX

product type :

antibody

product name :

Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free

catalog :

NB100-56505

quantity :

0.1 mg (also 0.025 mg)

price :

399 USD

clonality :

monoclonal

host :

mouse

conjugate :

DyLight 350

clone name :

98A1071

reactivity :

human, mouse, rat

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section

more info or order :

Novus Biologicals product webpage

citations: 40

Published Application/Species/Sample/Dilution	Reference
immunohistochemistry - frozen section; human	Stanisławowski M, Wisniewski P, Guzek M, Wierzbicki P, Adrych K, Smoczynski M, et al. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis. J Crohns Colitis. 2014;8:802-10 pubmed publisher
ELISA; human	Sandra F, Hendarmin L, Kukita T, Nakao Y, Nakamura N, Nakamura S. Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. Oral Oncol. 2005;41:637-44 pubmed
	Zhang W, Yu L, Wang F, Chen M, Li H. Rosavin regulates bone homeostasis through HDAC1-induced epigenetic regulation of EEF2. Chem Biol Interact. 2023;384:110696 pubmed publisher
	Hild V, Mellert K, M xf6 ller P, Barth T. Giant Cells of Various Lesions Are Characterised by Different Expression Patterns of HLA-Molecules and Molecules Involved in the Cell Cycle, Bone Metabolism, and Lineage Affiliation: An Immunohistochemical Study with a Review of the Literature. Cancers (Basel). 2023;15: pubmed publisher
	Kumar K, Datta K, Fornace A, Suman S. Total body proton and heavy-ion irradiation causes cellular senescence and promotes pro-osteoclastogenic activity in mouse bone marrow. Heliyon. 2022;8:e08691 pubmed publisher
	Lysitska A, Galanis N, Skandalos I, Nikolaidou C, Briza S, Fylaktou A, et al. Histology and Immunohistochemistry of Radial Arteries Are Suggestive of an Interaction between Calcification and Early Atherosclerotic Lesions in Chronic Kidney Disease. Medicina (Kaunas). 2021;57: pubmed publisher
	Zhang Q, Chen T, Zhang Y, Lyu L, Zhang B, Huang C, et al. MiR-30c-5p regulates adventitial progenitor cells differentiation to vascular smooth muscle cells through targeting OPG. Stem Cell Res Ther. 2021;12:67 pubmed publisher
	Jiang Y, Li J, Li G, Liu S, Lin X, He Y, et al. Osteoprotegerin interacts with syndecan-1 to promote human endometrial stromal decidualization by decreasing Akt phosphorylation. Hum Reprod. 2020;35:2439-2453 pubmed publisher
	Miyata T, Minami M, Kataoka H, Hayashi K, Ikedo T, Yang T, et al. Osteoprotegerin Prevents Intracranial Aneurysm Progression by Promoting Collagen Biosynthesis and Vascular Smooth Muscle Cell Proliferation. J Am Heart Assoc. 2020;9:e015731 pubmed publisher
	Bayer Alinca S, Saglam E, Zengin Celik T, Hacisalihoglu P, Doğan M. Is low level laser therapy or ozone therapy more effective for bone healing? Understanding the mechanisms of HIF-1α, RANKL and OPG. Biotech Histochem. 2020;:1-8 pubmed publisher
	Lee Y, Chan Y, Hsieh S, Lew W, Feng S. Comparing the Osteogenic Potentials and Bone Regeneration Capacities of Bone Marrow and Dental Pulp Mesenchymal Stem Cells in a Rabbit Calvarial Bone Defect Model. Int J Mol Sci. 2019;20: pubmed publisher
	Wang X, Cao Y, Liu Z, Wang Z, Chu X, Wang L, et al. Alveolar Bone Density Reduction in Rats Caused by Unilateral Nasal Obstruction. Balkan Med J. 2019;36:311-319 pubmed publisher
	Gegen T, Zhu Y, Sun Q, Hou B. Role of interleukin-33 in the clinical pathogenesis of chronic apical periodontitis. J Int Med Res. 2019;47:3332-3343 pubmed publisher
	Li D, Wang C, Li Z, Wang H, He J, Zhu J, et al. Nano-sized Al2O3 particle-induced autophagy reduces osteolysis in aseptic loosening of total hip arthroplasty by negative feedback regulation of RANKL expression in fibroblasts. Cell Death Dis. 2018;9:840 pubmed publisher
	El Kholy K, Freire M, Chen T, Van Dyke T. Resolvin E1 Promotes Bone Preservation Under Inflammatory Conditions. Front Immunol. 2018;9:1300 pubmed publisher
	Nozawa S, Inubushi T, Irie F, Takigami I, Matsumoto K, Shimizu K, et al. Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass. JCI Insight. 2018;3: pubmed publisher
	Scimeca M, Salustri A, Bonanno E, Nardozi D, Rao C, Piccirilli E, et al. Impairment of PTX3 expression in osteoblasts: a key element for osteoporosis. Cell Death Dis. 2017;8:e3125 pubmed publisher
	Larson S, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, et al. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate. 2013;73:932-40 pubmed publisher
	Boumans M, Thurlings R, Yeo L, Scheel Toellner D, Vos K, Gerlag D, et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012;71:108-13 pubmed publisher
	Witasp A, Carrero J, Hammarqvist F, Qureshi A, Heimburger O, Schalling M, et al. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. Eur J Clin Invest. 2011;41:498-506 pubmed publisher
	Tomlins C, Storey A. Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis. Carcinogenesis. 2010;31:2155-64 pubmed publisher
	Pohjolainen V, Taskinen P, Soini Y, Rysa J, Ilves M, Juvonen T, et al. Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol. 2008;39:1695-701 pubmed publisher
	Vandooren B, Cantaert T, Noordenbos T, Tak P, Baeten D. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008;58:718-29 pubmed publisher
	Waterman E, Cross N, Lippitt J, Cross S, Rehman I, Holen I, et al. The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. Int J Cancer. 2007;121:1958-66 pubmed
	Pettit A, Walsh N, Manning C, Goldring S, Gravallese E. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford). 2006;45:1068-76 pubmed
	Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 2006;42:415-20 pubmed
	Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25:3809-16 pubmed
	Gaudio A, Lasco A, Morabito N, Atteritano M, Vergara C, Catalano A, et al. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?. J Endocrinol Invest. 2005;28:677-82 pubmed
	Moschen A, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005;43:973-83 pubmed
	Moran C, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005;111:3119-25 pubmed
	Moschen A, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54:479-87 pubmed
	Vidal K, Serrant P, Schlosser B, van den Broek P, Lorget F, Donnet Hughes A. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol. 2004;287:G836-44 pubmed
	Vidal K, van den Broek P, Lorget F, Donnet Hughes A. Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. Pediatr Res. 2004;55:1001-8 pubmed
	Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-41 pubmed
	Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson R, Waage A, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002;100:3002-7 pubmed
	Komuro H, Olee T, Kuhn K, Quach J, Brinson D, Shikhman A, et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum. 2001;44:2768-76 pubmed
	Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater A, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001;98:2784-90 pubmed
	Pearse R, Sordillo E, Yaccoby S, Wong B, Liau D, Colman N, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-6 pubmed
	Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology. 2001;142:2205-12 pubmed
	Kobayashi Y, Hashimoto F, Miyamoto H, Kanaoka K, Miyazaki Kawashita Y, Nakashima T, et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. J Bone Miner Res. 2000;15:1924-34 pubmed

product information

master code :

NB100-56505

SKU :

NB100-56505

product name :

Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free

unit size :

0.1 mg (also 0.025 mg)

description :

The Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free from Novus is a mouse monoclonal antibody to Osteoprotegerin/TNFRSF11B. This antibody reacts with guinea pig,human,mouse,rabbit,rat. The Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free has been validated for the following applications: IF/IHC,ELISA,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry/ Immunofluorescence,Flow Cytometry,Immunoprecipitation,CyTOF-ready.

target :

Osteoprotegerin/TNFRSF11B

category :

Primary Antibodies

buffer :

PBS

clonality :

Monoclonal

clone :

98A1071

concentration :

1.0 mg/ml

conjugate :

Unconjugated

host :

Mouse

immunogen :

A peptide corresponding to the amino acids 20-37 TQETFPPKYLHYDEETSH of human Osteoprotegerin was used as immunogen for this antibody.

isotype :

IgG1 Kappa

purity :

Protein G purified

species :

Guinea Pig,Human,Mouse,Rabbit,Rat

specificity :

The Osteoprotegerin antibody, clone 98A1071, detects all forms of Osteoprotegerin including monomeric, dimeric and Osteoprotegerin bound to RANKL (Vandooren, 2008) as well as Osteoprotegerin bound to TRAIL (Sandra, 2006)

gene symbol :

TNFRSF11B

accessionNumbers :

O00300

applications :

IF/IHC,ELISA,Immunohistochemistry,Western Blot,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Immunocytochemistry/ Immunofluorescence,Flow Cytometry,Immunoprecipitation,CyTOF-ready

USD :

399 USD

alt names :

OCIFMGC29565, OPG, OPGtumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, TR1, tumor necrosis factor receptor superfamily, member 11b

storage :

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

more info or order :

Novus Biologicals product webpage